You are here
Carlos R. Camara-Lemarroy, Beatriz E. Ibarra-Yruegas, Rene Rodriguez-Gutierrez, Idanis Berrios-Morales, Carolina Ionete, Peter Riskind
Multiple Sclerosis and Related Disorders, Volume 12, February 2017, Pages 9-14
Emma Banwell, Bennis Pavisian, Liesly Lee, Anthony Feinstein
Multiple Sclerosis and Related Disorders, November 2016, Pages 123 - 126
Ellen Butler, Faith Matcham, Trudie Chalder
Multiple Sclerosis and Related Disorders, November 2016, Pages 145 - 168
Ana M. Novo, Sonia Batista, Joana Tenente, Carla Nunes, Carmo Macário, Lívia Sousa, Freire GonçalvesJournal of Clinical Neuroscience, Volume 33, November 2016, Pages 100–104
Abbey Valvano, Rebecca M. Floyd, Lauren Penwell-Waines, Lara Stepleman, Kimberly Lewis, Amy HouseJournal of Contextual Behavioral Science, Available online 22 July 2016
- Prof Feinstein discusses cognitive impairment in people with MS. Rates of impairment are approximately 30% early on in the disease...
- Prof Feinstein discusses his research into cannabis on cognition in people with MS. The question he is investigating is: Does...
- In this session, Prof Feinstein reviews neuropsychiatry abnormalities in people with MS, including depression, anxiety, pseudobulbar affect, euphoria, and bipolar...
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis
Karlyn A. Edwards, Ivan R. Molton, Amanda E. Smith, Dawn M. Ehde, Charles H. Bombardier, Samuel Battalio, Mark P. JensenArchives of Physical Medicine and Rehabilitation, Available online 23 March 2016
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial
Samuel F. Hunter, Mark Agius, Deborah M. Miller, Gary Cutter, Luigi Barbato, Kevin McCague, Xiangyi Meng, Neetu Agashivala, Peter Chin, Eric Hollander
Journal of the Neurological Sciences, June 2016, Pages 190 - 198